The Effect of Recombinant Human Interleukin-6 on Osteogenic Differentiation and YKL-40 Expression in Human, Bone Marrow-Derived Mesenchymal Stem Cells.

To access publisher's full text version of this article click on the hyperlink at the bottom of the pageHuman mesenchymal stem cells are an attractive cell source for tissue engineering and regenerative medicine applications, especially because of their differentiation potential toward the mesenchymal lineage. Furthermore, this cell type participates in the regeneration of tissue damage and plays an important role in immunity. Similarly, chitinase-like proteins have been proposed to aid in tissue remodeling, inflammation, and differentiation processes. The chitinase-like protein YKL-40 in particular is indicated in preventing damage to the extracellular matrix in response to proinflammatory cytokines, even though its biological function remains speculative. Finally, interleukin (IL)-6, a pleiotropic acute phase protein, participates in the regulation of bone turnover and immunoregulation. The physiological role of IL-6 in bone homeostasis is complex, exerting different effects on osteoblasts and osteoclasts depending on their differentiation stage. The aim of this study was to determine the effect of recombinant human IL-6 (5 ng/mL) on YKL-40 expression and osteogenic differentiation of human mesenchymal stem cells. Recombinant human IL-6 induced a donor-dependent change in mineralization and significantly promoted YKL-40 protein secretion. However, YKL-40 gene expression remained unaffected, and no statistically significant differences in the expression of osteogenic marker genes could be observed